Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Microvasculature

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Microvasculature. Displaying page 1 of 1.
    EudraCT Number: 2007-004612-31 Sponsor Protocol Number: BI3023_2002 Start Date*: 2008-05-29
    Sponsor Name:CSL Behring GmbH
    Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing acute bleeding while undergoing aortic replacement surgery
    Medical condition: Acute bleeding while undergoing aortic replacement surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061651 Aortic surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003234-32 Sponsor Protocol Number: UKM13_0018 Start Date*: 2014-12-02
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Pathological changes in the myocardial microvasculature - a MR-based quantification
    Medical condition: Patients with cardiovascular diseases and suspect of myocardial microvasculopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000240-17 Sponsor Protocol Number: ESTIMATE Start Date*: 2017-05-02
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes
    Medical condition: Coronary microvascular function in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10072685 Microvascular coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002046-20 Sponsor Protocol Number: FIBHGM-ECNC001-2019 Start Date*: 2020-07-22
    Sponsor Name:Fundación para la Innovación en Biomedicina-FIBMED
    Full Title: Effects of SGLT2 inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF.-CARDIA-STIFF.
    Medical condition: Patients with Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005406-32 Sponsor Protocol Number: 06087GM-A Start Date*: 2007-04-04
    Sponsor Name:Belfast City Hospital Trust
    Full Title: Doppler ultrasound investigation of microvasculature in health and disease
    Medical condition: Diabetes mellitus Hypertension
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004737-85 Sponsor Protocol Number: 1.3 Start Date*: 2018-12-11
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Alkaline Phosphatase to prevent ischemia reperfusion injury in living kidney transplantation
    Medical condition: Ischemia reperfusion injury in living donor kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003518-41 Sponsor Protocol Number: 2018-4765 Start Date*: 2019-10-03
    Sponsor Name:Radboudumc
    Full Title: Efficacy of Diltiazem to improve coronary microvascular dysfunction: A randomized clinical trial
    Medical condition: Coronary Microvascular Dysfunction (CMD). In CMD, ischemia is caused by impaired endothelial and/or non-endothelial coronary vasoreactivity resulting in the coronary microvasculature not dilating p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000825-38 Sponsor Protocol Number: M16-04EMPA-EYE Start Date*: 2016-10-20
    Sponsor Name:Hannover Medical School
    Full Title: SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial)
    Medical condition: Patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002153-35 Sponsor Protocol Number: GAP Start Date*: 2015-09-10
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of Glucagon-like peptide-1 stimulation on coronary microvascular dysfunction in women with angina pectoris and no obstructive stenosis of major coronary vessels
    Medical condition: Patients with angina pectoris and coronary microvascular dysfunction without significant stenosis og major coronary vessels
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004490-17 Sponsor Protocol Number: 72 Start Date*: 2014-12-17
    Sponsor Name:Bipebjerg University Hospital
    Full Title: Effect of ACE-Inhibition on Microvascular Function in Women with Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease.
    Medical condition: Microvascular dysfunction/microvascular angina
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005759-21 Sponsor Protocol Number: Start Date*: 2011-04-21
    Sponsor Name:University of Oxford
    Full Title: Can atorvastatin improve vascular function in women with a history preeclampsia? A Randomised, double-blinded, placebo-controlled crossover trial of atorvastatin in women with a history of preeclam...
    Medical condition: Cardiovascular disease in women with a history of preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10047065 - Vascular disorders 10047063 Vascular disorder peripheral LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018086-12 Sponsor Protocol Number: BI1412_2009 Start Date*: 2010-08-23
    Sponsor Name:Athena Care/ Isala Klinieken
    Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery
    Medical condition: Elective complex cardiac surgery is associated with excessive blood loss due to coagulopathy. Fibrinogen concentrate has been shown to reverse dilutional coagulopathy. In this double blinded, place...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009802 Coagulopathy LLT
    12.1 10000531 Acquired afibrinogenaemia LLT
    12.1 10005517 Blood fibrinogen LLT
    12.1 10011976 Decreased plasma fibrinogen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002428-10 Sponsor Protocol Number: KTxSGLT2i-22 Start Date*: 2023-03-06
    Sponsor Name:Oslo Univeristy Hospital - Rikshospitalet
    Full Title: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS?
    Medical condition: Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and va...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 17:11:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA